Baseline predictors of sustained fatigue onset in multiple sclerosis: A longitudinal survival analysis of the MS PATHS cohort
Multiple Sclerosis and Related Disorders · 2026
DOI: 10.1016/j.msard.2025.106915 ↗Kurz gefasst
Fachartikel in der Zeitschrift Multiple Sclerosis and Related Disorders, 2026. Verfasst von Mahsa Ghajarzadeh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Hauptthemen laut MEDLINE: Fatigue, Multiple Sclerosis. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Biogen.
Abstract (Originalsprache)
Fatigue is a common and debilitating symptom of multiple sclerosis (MS). While some patients experience fatigue prior to or at the time of diagnosis, a proportion develop this symptom during the disease course. This study aimed to identify factors associated with the future development of sustained fatigue in patients who were fatigue-free at baseline. We analyzed longitudinal data from a large, real-world cohort of people with MS, drawn from the Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) across 10 healthcare associations. Using Neuro-QoL-recommended T-score cut-points, participants' fatigue levels at baseline were categorized as "no fatigue" (T-score ≤ sample mean + 0.5 SD) or "fatigued" (T-score > sample mean + 0.5 SD). A multivariable time-to-event analysis was employed to determine predictors of 3-month sustained fatigue. Of the 6,327 fatigue-free participants included, 23.1 % developed sustained fatigue during an average (SD) of 2.5 (2.3) years of follow-up. Factors significantly associated with an increased risk of developing sustained fatigue included higher baseline physical disability (PDDS; HR = 1.38, 95 % CI: 1.15-1.67), depression (HR = 1.03, 95 % CI: 1.01-1.04), and anxiety (HR = 1.04, 95 % CI: 1.03-1.06). Conversely, better baseline cognitive function (HR = 0.96, 95 % CI: 0.95-0.97) was protective. Restricted Mean Survival Time (RMST) analysis showed that participants with a baseline PDDS ≤ 5 experienced an eight-month longer delay in the development of sustained fatigue (95 % CI: 5.0-11.1, P 5. Similarly, participants without baseline depression had a 17.4-month longer delay (95 % CI: 15.6-19.1, P < 0.001) compared to those with depression. In conclusion, nearly a quarter of initially fatigue-free patients developed sustained fatigue during medium-term follow-up. Baseline physical disability, depression, anxiety, and cognitive function were significant predictors of this outcome. These findings may guide interventions aimed at reducing the burden of fatigue, a disabling symptom in MS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: bnourba1@jhmi.edu.
Förderung
- Biogen
Zitieren
APA
Ghajarzadeh, M., Mowry, E. M., & Nourbakhsh, B. (2026). Baseline predictors of sustained fatigue onset in multiple sclerosis: A longitudinal survival analysis of the MS PATHS cohort. Multiple Sclerosis and Related Disorders. https://doi.org/10.1016/j.msard.2025.106915
Vancouver
Ghajarzadeh M, Mowry EM, Nourbakhsh B. Baseline predictors of sustained fatigue onset in multiple sclerosis: A longitudinal survival analysis of the MS PATHS cohort. Multiple Sclerosis and Related Disorders. 2026. doi:10.1016/j.msard.2025.106915
BibTeX
@article{Ghajarzadeh2026,
author = {Ghajarzadeh, Mahsa and Mowry, Ellen M and Nourbakhsh, Bardia},
title = {Baseline predictors of sustained fatigue onset in multiple sclerosis: A longitudinal survival analysis of the MS PATHS cohort},
journal = {Multiple Sclerosis and Related Disorders},
year = {2026},
doi = {10.1016/j.msard.2025.106915}
}
EUVIMED